Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAntonuzzo, Lorenzo
dc.contributor.authorBachet, Jean-Baptiste
dc.contributor.authorKuan, Feng-Che
dc.contributor.authorMacarulla Mercadé, Teresa
dc.contributor.authorLoupakis, Fotios
dc.contributor.authorPietrantonio, Filippo
dc.date.accessioned2021-11-10T11:04:37Z
dc.date.available2021-11-10T11:04:37Z
dc.date.issued2020-10-31
dc.identifier.citationLoupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, et al. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol. 2020 Oct 31;12:1–12.
dc.identifier.issn1758-8359
dc.identifier.urihttps://hdl.handle.net/11351/6519
dc.descriptionEsdeveniments adversos; Càncer colorectal metastàtic; Regorafenib
dc.description.sponsorshipThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Bayer.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesTherapeutic Advances in Medical Oncology;12
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer - Tractament
dc.subjectRecte - Càncer - Tractament
dc.subjectProteïnes quinases - Inhibidors - Ús terapèutic
dc.subject.meshColorectal Neoplasms
dc.subject.meshProtein-Tyrosine Kinases
dc.subject.mesh/antagonists & inhibitors
dc.subject.meshClinical Decision-Making
dc.titlePractical considerations in the use of regorafenib in metastatic colorectal cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/1758835920956862
dc.subject.decsneoplasias colorrectales
dc.subject.decsproteína-tirosina cinasas
dc.subject.decs/antagonistas & inhibidores
dc.subject.decstoma de decisiones clínicas
dc.relation.publishversionhttps://doi.org/10.1177/1758835920956862
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Loupakis F] Unit of Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy. [Antonuzzo L] Medical Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. [Bachet JB] Sorbonne Université, Service d’hépato-gastroentérologie, Hôpital Pitié Salpêtrière – Paris 6, APHP, Paris, France. [Kuan FC] Department of Hematology and Oncology, Chang-Gung Memorial Hospital, Chiayi, Taiwan. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pietrantonio F] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
dc.identifier.pmid33193826
dc.identifier.wos000587954500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple